# Aureon Laboratories

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aureon-laboratories

- Industry: Biotechnology
- Headquarters: West Des Moines, US
- Website: www.aureon.com
- Total disclosed funding: $27M
- Latest round: Series D (Mar 2, 2010)
- Investors on record: 5

## About

Aureon Laboratories specializes in delivering advanced connectivity and IT solutions to enhance business productivity across various sectors, including healthcare and finance.Founded in 2001 in West Des Moines, US, Aureon Laboratories provides connectivity and IT solutions. The company has undergone no significant pivots in its business strategy and operates independently. Its leadership includes CEO Ron Keller and Scott Behn. Aureon has raised a total of USD 7.00 mn across 4 deals, with the latest funding being a Series D round amounting to USD 7.00 mn, attracting investments from Atlas Venture, New Leaf Venture Partners, Pfizer Venture Investments, and Sprout Group.Aureon offers a comprehensive suite of connectivity and IT solutions, including managed IT services, voice and data solutions, cybersecurity, staffing, consulting, and contact center services. These solutions cater to diverse industries such as healthcare, education, finance, and government, solving challenges related to connectivity, operational efficiency, and customer engagement. With over 60,000 miles of fiber infrastructure, Aureon ensures reliable service with a 99.99% uptime, reaching customers beyond Iowa and throughout surrounding states.Aureon's revenue model combines subscription-based services and direct partnerships with businesses, leading to predictable income through long-term contracts and support agreements. The company engages in B2B transactions, offering tailored solutions such as managed IT, cybersecurity, and contact center support. Though specific pricing structures are proprietary, Aureon's flagship services are typically bundled to align with client needs, fostering long-lasting relationships that help businesses maintain growth and resilience in a competitive landscape.Aureon Laboratories has ceased operations and is no longer pursuing future growth plans.

## Funding rounds

- Series D, Mar 2, 2010, $7M — Atlas Venture, Sprout Group, New Leaf Venture Partners, Pfizer Venture Investments
- Series B, Jan 4, 2006, $2M — BD Ventures
- Series B, Jun 17, 2005, $18M — Atlas Venture, Sprout Group, Pfizer Venture Investments

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B, Series D
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series B, Series D
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series D
- BD Ventures (https://capitalatlas.ai/funds/bd-ventures) — Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series D